🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Joel Greenblatt’s ARQT Holdings & Trades

First Buy
Q2 2026
Duration Held
2 Quarters
Largest Add
Q2 2026
+19,032 Shares
Current Position
18,861 Shares
$498,496 Value

Joel Greenblatt's ARQT Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 18,861 shares of Arcutis Biotherapeutics, Inc. (ARQT) worth $498,496, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Joel Greenblatt has initiated a new position in ARQT, representing a fresh investment thesis on this company. Largest reduction occurred in Q3 2026, reducing 171 shares.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's Arcutis Biotherapeutics (ARQT) Holding Value Over Time

Track share changes against reported price movement

Quarterly Arcutis Biotherapeutics (ARQT) Trades by Joel Greenblatt

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 -171 Reduce 0.90% 18,861 $26.43
Q2 2026 +19,032 New Buy 19,032 $26.22

Joel Greenblatt's Arcutis Biotherapeutics Investment FAQs

Joel Greenblatt first purchased Arcutis Biotherapeutics, Inc. (ARQT) in Q2 2026, acquiring 19,032 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held Arcutis Biotherapeutics, Inc. (ARQT) for 2 quarters since Q2 2026.

Joel Greenblatt's largest addition to Arcutis Biotherapeutics, Inc. (ARQT) was in Q2 2026, adding 19,032 shares worth $499,019.

According to the latest 13F filing for Q3 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 18,861 shares of Arcutis Biotherapeutics, Inc. (ARQT), valued at approximately $498,496.

As of the Q3 2026 filing, Arcutis Biotherapeutics, Inc. (ARQT) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.

Joel Greenblatt's peak holding in Arcutis Biotherapeutics, Inc. (ARQT) was 19,032 shares, as reported at the end of Q2 2026.